BBOT
Manufacturing · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
256 E Grand Ave Ste 104, South San Franc...Website
www.bbotx.comRevenue
-Stock Symbol
BBOTIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About BBOT
BridgeBio Oncology Therapeutics (BBOT) is a clinical-stage biopharmaceutical company advancing a next generation pipeline of novel small molecule therapeutics targeting RAS and PI3K malignancies. Initially formed as a subsidiary of BridgeBio, BBOT completed a $200M private financing with external investors in 2024 with the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors.Explore more
BBOT Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is BBOT your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on BBOT recently announced quarterly report
BBOT, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at BBOT
Website visits: Recent activity has been detected on your website
Click to see if BBOT had a recent Job posting/layoffs
Product Launch: Get notified when BBOT launches new products
Funding: Get notified immidiatlly once BBOT has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if BBOT has recently received funding, and reach out quickly before it becomes old news!
Check out if BBOT is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined BBOT as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
BBOT is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
BBOT is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about BBOT.
BBOT Tech Stack
A closer look at the technologies used by BBOT
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Promotion
Executive Move
Executive Moves, Promotion
Promotion
Executive Move
Executive Moves, Promotion
Executive Move
Executive Moves, Board of Directors
Executive Move
Executive Moves, Board of Directors
BBOT News & Media
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced it awarded inducement grants on May 10, 2026 under BBOT’s 2025 Inducement Plan as a material inducement to the employment of one individual hired by BBOT in March 2026.BBOT Announces the Appointment of Pedro J. Beltran, PhD, as Chief Executive Officer, Idan Elmelech as Chief Operating Officer, and Neil Kumar, PhD, as Executive Chairman
Pedro J. Beltran, PhD, a seasoned executive who previously served as Chief Scientific Officer of BBOT, will assume the position of Chief Executive Officer, bringing his extensive drug development experience and scientific/business acumen to bear as the company’s top executiveBBOT Presents Preclinical Data Showing RAS:PI3Kα Breaker BBO-10203 Inhibits PI3Kα/AKT Signaling in HER2AMP Models at the AACR Annual Meeting 2026
BBO-10203 physically and allosterically disrupts the interaction between RAS and PI3Kα, leading to signaling inhibition without inhibiting the kinase activity of PI3Kα and with no observed hyperglycemiaBBOT Granted U.S. FDA Fast Track Designation for BBO-11818 for the Treatment of Adult Patients with Advanced KRAS-Mutant Pancreatic Ductal Adenocarcinoma
BBO-11818 is currently being evaluated in the Phase 1 KONQUER-101 trial in subjects with locally advanced unresectable or metastatic KRAS-mutant solid tumors
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding BBOT
Sign Up For FreeTo access detailed company insights
BridgeBio Oncology Therapeutics (BBOT) is a clinical-stage biopharmaceutical company advancing a next generation pipeline of novel small molecule therapeutics targeting RAS and PI3K malignancies. Initially formed as a subsidiary of BridgeBio, BBOT completed a $200M private financing with external investors in 2024 with the goal of improving outcome... Read More
